Monopar Therapeutics Inc. (MNPR Quick QuoteMNPR - Free Report) was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 50.4% in the past one-month time frame.

The company has seen one positive estimate revision in the past month, while its Zacks Consensus Estimate for the current quarter has also moved higher in the same time frame, suggesting that more solid trading could be ahead for Monopar Therapeutics. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Monopar Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

A better-ranked stock in the Medical – Biomedical and Genetics industry is Repligen Corporation (RGEN Quick QuoteRGEN - Free Report) , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Just Released: Zacks’ 7 Best Stocks for Today

Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.4% per year.

These 7 were selected because of their superior potential for immediate breakout.

See these time-sensitive tickers now >>